Moreover, CD45RO+CD62L− Th cell percentages in COVID-19 patients with poor outcomes were decreased only if compared to controls, while the CD45RO−CD62L− Th cell frequency in this group was higher compared to the patients with favorable disease outcomes (Figure 3C,D). The gene discussed is SELL; the disease is COVID-19.